Budoprutug for Primary Membranous Nephropathy
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
Recruiting
Phase 2
Interventional Study
Primary Membranous Nephropathy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 45 (estimated)
- Sponsor
- Climb Bio, Inc. · Industry
Who this trial is looking for
This trial is looking for people with a specific kidney condition called primary membranous nephropathy. Participants will test the safety of different doses of a medication called budoprutug.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with primary membranous nephropathy.
- I have positive anti-PLA2R antibodies.
- I have a B cell count of 40 cells/μL or more.
- I have protein in my urine of 2.0 g/g or more.
- I have good kidney function (eGFR of 35 mL/min/1.73 m² or more).
- I am on stable RAAS inhibitor therapy.
- My blood pressure is less than 150/90 mmHg.
- I am willing to use effective contraception.
You may not be able to join if
- I have secondary membranous nephropathy.
- I have rapidly progressive kidney disease or other serious kidney problems.
- I have had B cell-depleting therapy in the last 24 weeks.
- I have used immunosuppressants recently.
- I have an active or high-risk infection.
- I have a history of cancer.
- I am pregnant or breastfeeding.
- I have had major surgery or hospitalization recently.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Confirmed diagnosis of PMN with positive anti-PLA2R antibodies
* CD19+ B cell count ≥40 cells/μL
* UPCR ≥2.0 g/g
* eGFR ≥35 mL/min/1.73 m²
* Stable RAAS inhibitor therapy
* Blood pressure \<150/90 mmHg at baseline
* Adequate hematologic, hepatic, and renal function
* Willing t…
Contacts